rare diseases

Graphic image of an arrow nailing the bullseye of a target
Biotech

Cogent hits primary endpoint, building case for Blueprint rival

The phase 3 trial has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.
Nick Paul Taylor Jul 7, 2025 9:16am
Congress senate house government US
Favicon Fierce Pharma

Senate revives Orphan Cures Act in Trump's tax bill

Jun 30, 2025 10:09am
ice skate on the ice

Minovia skates SPAC-wards into public market

Jun 25, 2025 10:33am
Cartoon of businessmen standing around a broken target

Vigil's rare brain disease drug flunks phase 2 study

Jun 4, 2025 9:45am
Sanofi
Favicon Fierce Pharma

Sanofi buys Blueprint for $9.1B, its largest deal in 7 years

Jun 2, 2025 11:09am
rare diseases

Stealth CEO questions FDA rejection of rare disease drug

May 29, 2025 2:27pm